Are patients with bleeding disorders receiving plasma-derived products at increased risk of acquiring COVID-19?

No. The current process of manipulation of plasma derived products eliminates SARS-Cov-2. SARS-CoV-2 is a large virus (120 nm diameter) with a lipid envelope. Therefore, it is highly susceptible to processing steps used in processing such as solvent-detergent, low pH incubation, caprylate-pasteurization or dry-heat treatments, nanofiltration or fraction process and others. Please refer to the Medical and Scientific Advisory Council (MASAC) for the World Federation of Hemophilia (WFH) open letter...